The call highlighted significant revenue growth, a strong cash position from a successful rights issue, and robust gross margins. However, challenges include a net loss, seasonal sales impact, particularly in Germany, and delays in securing a partnership in Japan. The sentiment is balanced with positive growth indicators and existing challenges.

Company Guidance

During Oncopeptides' third-quarter earnings call for 2025, CEO Sofia Heigis and CFO Henrik Bergentoft provided a detailed overview of the company's financial and operational performance. They reported a significant 174% year-over-year increase in net sales to SEK 20.2 million, marking the fourth consecutive quarter of growth. The company's gross profit reached SEK 19.9 million with an impressive 99% gross margin, reflecting strong business scalability. Operating expenses decreased by 3%, contributing to an improved EBIT of minus SEK 47.1 million compared to minus SEK 61.3 million last year. Despite continued investments, the net loss was SEK 60.9 million, impacted by a noncash fair valuation of warrants. Oncopeptides' cash position was SEK 148 million after a successful rights issue oversubscribed by 157%, providing financial flexibility to support ongoing growth and partnership discussions, particularly in Japan. The company's European market showed robust commercial traction, with Italy leading growth, while Spain achieved full regional access, and Germany demonstrated resilience. On the scientific front, Pepaxti gained recognition through inclusion in clinical guidelines and real-world data presentations, further solidifying its market position. Looking forward, Oncopeptides aims for profitability by the end of 2026, driven by strategic cost control, strong revenue growth, and expanded market access.

Significant Revenue Growth

Net sales reached SEK 20.2 million, representing a 174% increase year-over-year, marking the fourth consecutive quarter-over-quarter growth.

Record Cash Position from Rights Issue

Cash position at the end of the period was SEK 147.9 million after a rights issue of SEK 150 million, which was oversubscribed by 157%.

Strong Gross Margin

Gross profit reached SEK 19.9 million, reflecting a robust gross margin of 99%.

Continued Commercial Traction in Europe

Italy led the growth, Spain reached full regional access, and Germany showed more resilience than the previous year.

Expansion in Scientific Recognition

Pepaxti gained credibility and recognition, resulting in inclusion in clinical guidelines and presentations at major scientific meetings.

Oncopeptides AB (SE:ONCO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SE:ONCO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2025 (Q4)	-0.19 / -	-0.365	―	―	―
Nov 05, 2025	2025 (Q3)	-2.58 / -0.27	-0.273	1.10% (<+0.01)	―	―
Aug 21, 2025	2025 (Q2)	- / -0.30	-0.452	33.63% (+0.15)	―	―
May 15, 2025	2025 (Q1)	- / -0.27	-0.707	61.67% (+0.44)	―	―
Feb 27, 2025	2024 (Q4)	- / -0.36	-0.605	39.67% (+0.24)	―	―
Nov 07, 2024	2024 (Q3)	- / -0.27	-0.301	9.30% (+0.03)	―	―
Aug 14, 2024	2024 (Q2)	- / -0.45	-0.416	-8.65% (-0.04)	―	―
May 30, 2024	2024 (Q1)	- / -0.71	-0.531	-33.15% (-0.18)	―	―
Feb 27, 2024	2023 (Q4)	- / -0.60	-0.678	10.77% (+0.07)	―	―
Nov 08, 2023	2023 (Q3)	- / -0.30	-0.672	55.21% (+0.37)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SE:ONCO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 05, 2025	kr5.79	kr5.01	-13.47%
Aug 21, 2025	kr4.75	kr3.80	-20.00%
May 15, 2025	kr1.90	kr1.84	-3.16%
Feb 27, 2025	kr1.76	kr1.59	-9.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Oncopeptides AB (SE:ONCO) report earnings?

Oncopeptides AB (SE:ONCO) is schdueled to report earning on Feb 19, 2026, Before Open (Confirmed).

What is Oncopeptides AB (SE:ONCO) earnings time?

Oncopeptides AB (SE:ONCO) earnings time is at Feb 19, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Oncopeptides AB stock?

The P/E ratio of Oncopeptides AB is N/A.

What is SE:ONCO EPS forecast?

SE:ONCO EPS forecast for the fiscal quarter 2025 (Q4) is -0.19.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing